EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC 4.0

Prognostic Testing for Prostate Cancer—A Cost-Effectiveness Analysis Comparing a Prostatype P-Score Biomarker Approach to Standard Clinical Practice

Adam Fridhammar iD, Oskar Frisell iD, Karin Wahlberg iD, Emelie Berglund iD, Pontus Röbeck iD, Sofie Persson iD

PharmacoEconomics · 2025

DOI: 10.1007/s40273-024-01466-9 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift PharmacoEconomics, 2025. Verfasst von Adam Fridhammar und 5 weiteren Autor:innen. Beteiligte Einrichtung: The Swedish Institute for Health Economics, Lund, Sweden. adam.fridhammar@ihe.se. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Sponsorship for this analysis and article was provided by Prostatype Genomics AB to the Swedish Institute for Health Economics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsBiomarkers, TumorHumansMaleCost-Benefit AnalysisPrognosisQuality-Adjusted Life YearsMiddle AgedSwedenProstate-Specific AntigenNeoplasm GradingMarkov ChainsRisk AssessmentDecision Support TechniquesDecision TreesWatchful WaitingAgedCost-Effectiveness Analysis

Substanzen

Biomarkers, TumorProstate-Specific Antigen

Autor:innen und Institutionen

  • The Swedish Institute for Health Economics, Lund, Sweden. adam.fridhammar@ihe.se.
  • The Swedish Institute for Health Economics, Lund, Sweden.
  • Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Solna, Sweden.
  • Prostatype Genomics AB, Stockholm, Sweden.
  • Department of Urology, Uppsala University Hospital, Uppsala, Sweden.
  • Department of Clinical Sciences, Lund University, Lund, Malmö, Sweden.

ORCID-Profile: Adam Fridhammar, Oskar Frisell, Karin Wahlberg, Emelie Berglund, Pontus Röbeck, Sofie Persson

Förderung

  • Sponsorship for this analysis and article was provided by Prostatype Genomics AB to the Swedish Institute for Health Economics

Zitieren

APA

Fridhammar, A., Frisell, O., Wahlberg, K., Berglund, E., Röbeck, P., & Persson, S. (2025). Prognostic Testing for Prostate Cancer—A Cost-Effectiveness Analysis Comparing a Prostatype P-Score Biomarker Approach to Standard Clinical Practice. PharmacoEconomics. https://doi.org/10.1007/s40273-024-01466-9

Vancouver

Fridhammar A, Frisell O, Wahlberg K, Berglund E, Röbeck P, Persson S. Prognostic Testing for Prostate Cancer—A Cost-Effectiveness Analysis Comparing a Prostatype P-Score Biomarker Approach to Standard Clinical Practice. PharmacoEconomics. 2025. doi:10.1007/s40273-024-01466-9

BibTeX
@article{Fridhammar2025,
  author = {Fridhammar, Adam and Frisell, Oskar and Wahlberg, Karin and Berglund, Emelie and Röbeck, Pontus and Persson, Sofie},
  title = {Prognostic Testing for Prostate Cancer—A Cost-Effectiveness Analysis Comparing a Prostatype P-Score Biomarker Approach to Standard Clinical Practice},
  journal = {PharmacoEconomics},
  year = {2025},
  doi = {10.1007/s40273-024-01466-9}
}
Kostenlos starten →